glp-1 and stroke Risk of major adverse cardiovascular events associated with treatment with or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stroke Prevention Guideline Adds Recs
Description
The former is a calculated risk that many researchers accept with the understanding that BUDs include a safety margin
This risk was more pronounced in weight-loss scenarios, where higher doses of GLP-1RAs, such as those used with liraglutide and semaglutide, resulted in more significant weight reduction and a correspondingly higher incidence of gallstone-related complications
This applies whether you have used the pen or not
Over weeks of consistent under-dosing due to bubbles, you might conclude that semaglutide is not working for you when the real problem is that you have never been taking the full dose
